← Leaderboards
Donald C. Goff
Massachusetts General Hospital
$14,005,830
Attributed
$15,547,151
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,547,151 · 12
By mechanism
R01$8,485,144 · 5
R33$2,086,680 · 1
K24$1,630,891 · 1
R61$1,019,329 · 1
U01$959,478 · 1
R34$762,750 · 1
Top collaborators
- Lila Davachi5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jordan W Smoller$49,248,068
- Scott L Rauch$5,523,279
Others in their field
Top investigators on “Schizophrenia”
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$104,668,216
- Raquel E Gur · University Of Pennsylvania$60,189,770
- Mark J Daly · Broad Institute, Inc.$48,989,393
- John M Kane · Long Island Jewish Medical Center$45,235,871
- Carrie E Bearden · University Of California Los Angeles$42,025,230
- Scott W Woods · Yale University$41,221,536
Research focus
SchizophreniaAntipsychotic AgentsClinical ResearchResponseCognitionSymptomsQuality Of LifePharmaceutical PreparationsPharmacologyPlacebosSiteDesignPropertyDoseLinkProtocols DocumentationSerineHuman SubjectCognitivePrimary OutcomeMental Disorder ChemotherapyProgramsPlacebo ControlHippocampus (Brain)
Grant awards (55)
2/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial$254,250
R01 · FY2025 · MH · contact PI
2/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial$254,250
R01 · FY2024 · MH · contact PI
2/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial$254,250
R01 · FY2023 · MH · contact PI
Levetiracetamin in First Episode Psychosis$673,843
R33 · FY2022 · MH · contact PI
Hippocampal memory circuits in delusions$586,392
R01 · FY2022 · MH · contact PI
2/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial$254,250
R01 · FY2022 · MH · contact PI
Levetiracetamin in First Episode Psychosis$653,759
R33 · FY2021 · MH · contact PI
Hippocampal memory circuits in delusions$600,095
R01 · FY2021 · MH · contact PI
2/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial$211,875
R01 · FY2021 · MH · contact PI
Levetiracetamin in First Episode Psychosis$759,078
R33 · FY2020 · MH · contact PI
Hippocampal memory circuits in delusions$607,651
R01 · FY2020 · MH · contact PI
Hippocampal memory circuits in delusions$591,326
R01 · FY2019 · MH · contact PI
Hippocampal memory circuits in delusions$697,178
R01 · FY2018 · MH · contact PI
Levetiracetamin in First Episode Psychosis$506,581
R61 · FY2018 · MH · contact PI
Levetiracetamin in First Episode Psychosis$512,748
R61 · FY2017 · MH · contact PI
Dcycloserine Augmentation of Cognitive Behavioral Therapy for Delusions$254,250
R34 · FY2016 · MH · contact PI
Dcycloserine Augmentation of Cognitive Behavioral Therapy for Delusions$254,250
R34 · FY2014 · MH · contact PI
Citalopram in First Episode Schizophrenia$591,843
R01 · FY2013 · MH · contact PI
Dcycloserine Augmentation of Cognitive Behavioral Therapy for Delusions$254,250
R34 · FY2013 · MH · contact PI
Citalopram in First Episode Schizophrenia$122,532
R01 · FY2013 · MH · contact PI
Citalopram in First Episode Schizophrenia$578,480
R01 · FY2012 · MH · contact PI
Citalopram in First Episode Schizophrenia$138,958
R01 · FY2012 · MH · contact PI
Citalopram in First Episode Schizophrenia$490,392
R01 · FY2011 · MH · contact PI
New Treatment and Mechanisms in Schizophrenia$188,307
K24 · FY2011 · MH · contact PI
Citalopram in First Episode Schizophrenia$495,621
R01 · FY2010 · MH · contact PI
Folate in Schizophrenia$283,500
R01 · FY2010 · MH · contact PI
New Treatment and Mechanisms in Schizophrenia$188,327
K24 · FY2010 · MH · contact PI
Relapse Prevention: Long-Acting Atypical Antipsychotics$170,280
U01 · FY2010 · MH · contact PI
Citalopram in First Episode Schizophrenia$502,969
R01 · FY2009 · MH · contact PI
Folate in Schizophrenia$283,500
R01 · FY2009 · MH · contact PI
Relapse Prevention: Long-Acting Atypical Antipsychotics$202,841
U01 · FY2009 · MH · contact PI
New Treatment and Mechanisms in Schizophrenia$188,348
K24 · FY2009 · MH · contact PI
Folate in Schizophrenia$283,500
R01 · FY2008 · MH · contact PI
Relapse Prevention: Long-Acting Atypical Antipsychotics$203,402
U01 · FY2008 · MH · contact PI
New Treatment and Mechanisms in Schizophrenia$188,695
K24 · FY2008 · MH · contact PI
Folate in Schizophrenia$283,500
R01 · FY2007 · MH · contact PI
Relapse Prevention: Long-Acting Atypical Antipsychotics$203,402
U01 · FY2007 · MH · contact PI
New Treatment and Mechanisms in Schizophrenia$189,024
K24 · FY2007 · MH · contact PI
Relapse Prevention: Long-Acting Atypical Antipsychotics$179,553
U01 · FY2006 · MH · contact PI
New Treatment and Mechanisms in Schizophrenia$137,638
K24 · FY2005 · MH
New Treatment and Mechanisms in Schizophrenia$137,638
K24 · FY2004 · MH
New Treatment and Mechanisms in Schizophrenia$137,638
K24 · FY2003 · MH
A TRIAL OF D-CYCLOSERINE IN SCHIZOPHRENIA$200,768
M01 · FY2002 · RR
A TRIAL OF D-CYCLOSERINE IN SCHIZOPHRENIA$200,768
M01 · FY2002 · RR
New Treatment and Mechanisms in Schizophrenia$137,638
K24 · FY2002 · MH
NMDA RECEPTOR FUNCTION IN SCHIZOPHRENIA$0
P50 · FY2002 · MH
NMDA RECEPTOR FUNCTION IN SCHIZOPHRENIA$0
P50 · FY2002 · MH
A TRIAL OF D-CYCLOSERINE IN SCHIZOPHRENIA$200,768
M01 · FY2001 · RR
New Treatment and Mechanisms in Schizophrenia$137,638
K24 · FY2001 · MH
A TRIAL OF D-CYCLOSERINE IN SCHIZOPHRENIA$0
M01 · FY2001 · RR
NMDA RECEPTOR FUNCTION IN SCHIZOPHRENIA$0
P50 · FY2001 · MH
GLYCINE AND D-CYCLOSERINE IN SCHIZOPHRENIA$118,832
R01 · FY2000 · MH
A TRIAL OF D-CYCLOSERINE IN SCHIZOPHRENIA$575
M01 · FY2000 · RR
NMDA RECEPTOR FUNCTION IN SCHIZOPHRENIA$0
P50 · FY2000 · MH
A TRIAL OF D-CYCLOSERINE IN SCHIZOPHRENIA$0
M01 · FY2000 · RR